What is Semba Biosciences?
Semba Biosciences, established in 2005 and headquartered in Madison, Wisconsin, is a life science entity recognized for its pioneering work in continuous chromatography. The company's Octave® Systems are instrumental in the efficient and scalable purification of biomolecules, serving critical roles within the food, chemical, and pharmaceutical industries. With the introduction of its Octave® BIO and ProGMP products, Semba Biosciences is extending the application of continuous chromatography to biopharmaceutical downstream process development and single-use manufacturing, positioning itself as a key player in advanced bioprocessing solutions.
How much funding has Semba Biosciences raised?
Semba Biosciences has raised a total of $330K across 2 funding rounds:
Debt
$150K
Debt
$180K
Debt (2020): $150K with participation from PPP
Debt (2021): $180K led by PPP
Key Investors in Semba Biosciences
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Semba Biosciences?
The substantial capital infusion, contextualized as a large-scale late-stage funding, signals Semba Biosciences' readiness for significant expansion and market penetration. This strategic backing is likely to fuel further research and development, enhance manufacturing capabilities, and broaden the company's commercial reach. The focus on biopharmaceutical applications suggests a strategic pivot towards higher-value markets, aiming to solidify its position in advanced downstream processing and single-use manufacturing technologies. Future growth will likely involve strategic partnerships and increased market adoption of its proprietary Octave® platform.
See full Semba Biosciences company page
